Exploring Toxicity of Nanomedicines       


Medical, Health Informatics and Computational Biology Accomplishment | 2013

IBM researchers: Ruhong Zhou, Seung-gu Kang, Tien Huynh, Binquan Luan

Where the work was done: IBM T.J. Watson Research Center

What we accomplished: Nanomedicine holds great promise towards the effective treatment of many fatal diseases with a market potential in excess of hundreds of billions of dollars. Nanoscale particles, such as carbon nanotubes (CNTs) and graphene, have emerged as promising materials in various biomedical applications. To fully facilitate these applications, it is imperative to investigate the potential toxicity involved with these nanomaterials. IBM is a pioneer in using large-scale modeling to study this new exciting field

Along with external experimental collaborators, for the first time, IBM: (1) revealed two important potential pathways for protein function disruption, (2) identified ways to reduce the cytotoxicity of CNTs, (3) revealed molecular mechanisms for Gd@C82(OH)22’s anti-cancer capability and (4) discovered graphene’s anti-bacterial activity. These works help shed light and gain deeper understanding of the underlying mechanism of cytotoxicity and implications in nanomedicines. 

Related links: IBM's nanomedicine work has been published as feature articles in:

Image credit: IBM Research

BACK TO MEDICAL, HEALTH INFORMATICS and COMPUTATIONAL BIOLOGY
BACK TO IBM RESEARCH ACCOMPLISHMENTS